Powered by Smartsupp

Akkermansia muciniphila: what is it and what do human studies show?

KINGRAY ACADEMY · DIGESTION AND GUT HEALTH · 04

What is Akkermansia muciniphila, and does research prove a weight-loss effect?

It is a bacterium naturally found in the human gut that can use mucin. Studies of particular preparations have produced differing findings; they do not establish universal weight loss or a need for everyone to supplement it. [1] [2] [3] [4]

We compare the 2019 pilot study with two studies from 2026, separating weight maintenance after dieting, insulin sensitivity and the limits of applying findings to other preparations.

Author: Ing. František Kokoš – nutrition adviserUpdated:

What is Akkermansia muciniphila?

Akkermansia muciniphila is a bacterium naturally found in the human gut. It can use mucin, a major component of intestinal mucus. Derrien and colleagues described it as a separate species in 2004. [1]

Using mucin is a biological property. On its own, it demonstrates neither damage to nor improvement of the intestinal barrier. The host's own cells produce the mucus; the bacterium is part of this environment, not a substitute for those cells.

↑ Back to article contents

What have human studies investigated?

The 2019 pilot study

Depommier and colleagues tested live and pasteurised forms in adults with overweight or obesity and insulin resistance. They enrolled 40 people; 32 completed the study. Some metabolic markers improved with the pasteurised form, but the difference in body weight compared with placebo was not statistically significant. This small, three-month trial provided a basis for further research. [2]

Weight maintenance: a 2026 trial

Mount and colleagues studied 90 adults with overweight or obesity. A low-energy diet was followed by 24 weeks of weight maintenance with a specific pasteurised MucT strain or placebo. The group receiving that strain regained less weight on average. This finding concerns a defined programme after weight loss, not a universal weight-loss effect. [3]

Insulin sensitivity: another 2026 trial

Suenaert and colleagues studied 142 adults with metabolic syndrome. After four months, the primary measure of whole-body insulin sensitivity did not differ from placebo in the main analysis population. Some favourable findings appeared in subsequent exploratory subgroup analyses. These must be distinguished from the trial's primary result. [4]

↑ Back to article contents

What are the limits of these findings?

The bacterium's natural presence in the gut, a live culture and a heat-inactivated, pasteurised preparation are different situations. Results depend on the strain, processing, study population and duration. They cannot automatically be transferred to another preparation or every individual.

Distinguish the primary outcome from additional analyses, and read the funding and conflict-of-interest disclosures. Several authors of study [4] report links to the company developing the preparation. Further independent verification matters. [4]

Research overview: These studies do not constitute advice to take Akkermansia, choose a product or change treatment. A single microbiome test value cannot establish a need for supplementation. [5]

↑ Back to article contents

In plain language

An interesting bacterium is not automatically a suitable supplement. A finding must be linked to the particular preparation, population and question studied.

[2] [3] [4] [5]

↑ Back to article contents

Frequently asked questions

Are live and pasteurised Akkermansia the same?

No. Pasteurisation inactivates the bacteria. Findings must refer to the specific strain and form that the researchers tested.

[2] [3] [4]

Do the studies prove weight loss for everyone?

No. The 2026 trial studied weight maintenance after dieting over 24 weeks. It does not establish a universal weight-loss effect.

[3]

Were all the trials positive?

No. In the trial of 142 adults, the primary insulin sensitivity measure did not differ from placebo after four months. Exploratory subgroups do not change that main result.

[4]

Does a low test value mean I need a supplement?

No. A single value from a commercial microbiome test establishes neither a diagnosis nor a need for a specific supplement.

[5]

Scientific references

  1. Derrien et al. (2004): Akkermansia muciniphila — species description
  2. Depommier et al. (2019): a proof-of-concept exploratory study
  3. Mount et al. (2026): randomised trial of weight-loss maintenance
  4. Suenaert et al. (2026): metabolic syndrome and insulin sensitivity
  5. Porcari et al. (2025): International consensus statement on microbiome testing in clinical practice

Ing. František Kokoš
Author: Ing. František Kokoš
Ing. František Kokoš – Author of KINGRAY Academy and Advice Corner
Technician, nutrition adviser (graduate of the 150-hour Welko retraining programme, 2025) and creator of the KINGRAY nutraceuticals concept. Years of developing the BIOquant medical device and working with blood rheology and tissue oxygenation led him to realise that bodily health requires the full picture – linking microcirculation, cellular energy and proper nutrition. In his articles, he looks for the balance where the body understands and cooperates with us.
He is the author of the book Liečba svetlom (Light Therapy, ISBN 978-80-970512-0-4), co-author of the publication BIOquant – polovodičová laserová terapia (BIOquant – Semiconductor Laser Therapy, ISBN 978-80-970512-2-8), and originator of patents in light technologies (US9731145B2, SK5457Y1).
%s ...
%s
%image %title %code %s
%s